Product Summary
Osimertinib Mesylate Intermediate CAS 1421373-66-1 Items Standards Results Appearance White to light yellow solid powder Light yellow solid powder Identification By IR Complies By HPLC Complies Solubility Soluble in Dimethylsulfoxide,slightly soluble in Ethanol and Acetonitrile,with pH dependent ...
Osimertinib Mesylate AZD9291 White Powder 1421373-66-1 For Cancer Treatment
Basic Properties
Trading Properties
White Powder Osimertinib Mesylate
,CAS 1421373-66-1 AZD9291
,Mesylate AZD9291 White Powder
| Items | Standards | Results |
| Appearance | White to light yellow solid powder | Light yellow solid powder |
| Identification | By IR | Complies |
| By HPLC | Complies | |
| Solubility | Soluble in Dimethylsulfoxide,slightly soluble in Ethanol and Acetonitrile,with pH dependent aqueous solubility | Complies |
| Water Content(KF) | ≤ 1.00% | 0.38% |
| Residue on Ignition | ≤ 0.10% | 0.07% |
| Heavy Metals | ≤ 20ppm | Complies |
| Mesylate | 15.20%~18.20% | 17.20% |
| Residual Solvents | Acetonitrile: ≤410ppm | ND |
| Acet: ≤5000ppm | 2500ppm | |
| Tetrahydrofuran: ≤720ppm | ND | |
| Related Substances | Maximum single impurity: ≤0.20% | 0.05% |
| Total impurities: ≤1.00% | 0.08% | |
| Assay (HPLC basis on drying) |
98.00%~102.00% | 99.96% |
| Particle Size | D90: ≤100µm | Complies |
| Reference Standard | In-house Standard | |
| Conclusion | The product complied to In-house standard. | |
| Storage | Preserve in tight,light-resistant containers in a cool place | |

- Cancer Treatment: Primarily used in the treatment of non-small cell lung cancer (NSCLC) that has developed resistance to first- and second-generation EGFR inhibitors, particularly those harboring the T790M mutation.
- Therapeutic Agent in Clinical Trials: Currently being investigated in clinical trials for other types of cancers, exploring its potential as a broad-spectrum antitumor agent.
- Combination Therapy: Researchers are exploring the use of Osimertinib Mesylate in combination with other therapies to enhance treatment efficacy and overcome drug resistance.
- Inhibition of EGFR Mutations: Binds covalently and irreversibly to the EGFR, particularly the T790M mutation, effectively inhibiting its signaling pathways and tumor growth.
- Improved Patient Outcomes: By targeting resistant EGFR mutations, Osimertinib Mesylate has demonstrated improved progression-free survival and overall survival in clinical trials.
- Minimal Off-Target Effects: Mutation-selective properties minimize off-target effects, reducing potential adverse reactions and improving treatment
- Packaging Options
- ≤50kg: Express delivery recommended (DDU service)
- ≤500kg: Air shipping recommended (CIF service)
- >500kg: Sea shipping recommended (FOB, CFR, or CIF service)
- For high-value products: Air shipping and express delivery recommended for safety
-
J98% purity , nice
-
Rgood quality cheapest price ,very nice
-
Jvery good high purity, good use
Please use our online inquiry contact form below if you have any questions, our team will get back to you as soon as possible.